A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors

NCT05576077 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

31

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision

Conditions

Breast Cancer
Colorectal Cancer
Uveal Melanoma
Cutaneous Melanoma
Non-Small Cell Lung Cancer
Head and Neck Squamous Cell Carcinoma

Interventions

BIOLOGICAL: TBio-4101
DRUG: Pembrolizumab

Sponsor

Turnstone Biologics, Corp.